Almirall, S.A.
Clinical trials sponsored by Almirall, S.A., explained in plain language.
A pharmaceutical company focused on dermatology and medical aesthetics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for painful skin condition: experimental drug LAD328 enters phase 2 trial Results expected Feb 2027 (estimated)
- Eczema drug trial could mean fewer shots for patients Results expected Apr 2027 (estimated)
- New hope for HS sufferers: LAD191 enters Mid-Stage trial Results expected May 2027 (estimated)
- New drug LAD106 enters first human safety tests Results expected May 2027 (estimated)
- New drug could help regrow hair in severe alopecia Results expected Jun 2027 (estimated)
-
New shot could help eczema sufferers who Don't respond to steroids
Disease control Recruiting nowThis Phase 3 study tests whether lebrikizumab, an injectable drug, can safely and effectively treat nummular eczema in adults who haven't gotten enough relief from topical steroids or can't use them. About 270 participants will receive either lebrikizumab or a placebo injection. …
Phase 3 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug could help regrow hair in severe alopecia
Disease control Recruiting nowThis study tests a drug called LAD603 in 136 adults with severe to very severe alopecia areata, a condition causing significant hair loss. Participants will receive either the drug or a placebo to see if it helps regrow hair and is safe. The main goal is to measure changes in hai…
Phase 2 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for HS sufferers: LAD191 enters Mid-Stage trial
Disease control Recruiting nowThis study tests a new injectable drug called LAD191 in 200 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition causing abscesses and scarring. Participants will receive either LAD191, a placebo, or an active comparator (adalimumab) to see if LA…
Phase 2 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for painful skin condition: experimental drug LAD328 enters phase 2 trial
Symptom relief Recruiting nowThis study tests whether the experimental drug LAD328 can reduce symptoms of hidradenitis suppurativa, a chronic skin condition causing painful lumps. About 50 adults with moderate-to-severe disease will receive either LAD328 or a placebo. The main goal is to see if the drug lead…
Phase 2 • Sponsor: Almirall, S.A. • Aim: Symptom relief
Last updated Aug 19, 2026 00:00 UTC
-
New drug LAD106 enters first human safety tests
Knowledge-focused Recruiting nowThis early-stage study is testing a new drug called LAD106 in 93 healthy adults aged 18 to 45. The main goal is to see if it is safe and how the body processes it. Participants will receive either LAD106, a similar drug (lebrikizumab), or a placebo. This research is a first step …
Phase 1 • Sponsor: Almirall, S.A. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC